Comerica (NYSE:CMA) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.55 by 1.18 percent. This is a 55.42 percent increase over earnings of $1.66 per share from the same period last year.
Incannex Received IRB Approval For RePOSA Phase 2/3 Clinical Trial Protocol To Assess IHL-42X Drug In Patients With Obstructive Sleep Apnea
Incannex Healthcare Inc. (NASDAQ:IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine
